ARDM - Aradigm Corporation
| Previous Close | 1.1600 |
| Open | 1.2000 |
| Bid | 1.2500 x 2900 |
| Ask | 1.2700 x 900 |
| Day's Range | 1.2000 - 1.3000 |
| 52 Week Range | 1.0300 - 7.3500 |
| Volume | 51,123 |
| Avg. Volume | 46,115 |
| Market Cap | 19.134M |
| Beta (3Y Monthly) | 0.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1110 |
| Earnings Date | Oct 31, 2018 - Nov 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 1996-03-01 |
| 1y Target Est | 10.00 |
- GlobeNewswire•7 days ago
Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team
- Dr. Matkovits is an industry leader with 20+ years of proven global drug development success bringing 4 approved medicines to several global markets - - Frank Calamusa, CSCP,.
- GlobeNewswire•27 days ago
Consolidated Research: 2018 Summary Expectations for Community Health, Aradigm, Avnet, Sanchez Energy, Black Stone Minerals, and Navient — Fundamental Analysis, Key Performance Indications
NEW YORK, Sept. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Associated Press•2 months ago
Aradigm: 2Q Earnings Snapshot
The Hayward, California-based company said it had a loss of 25 cents per share. The specialty pharmaceutical company posted revenue of $256,000 in the period. The company's shares closed at $1.38. A year ...
- Business Wire•2 months ago
Aradigm Announces Second Quarter 2018 Financial Results
Aradigm Corporation today announced financial results for the second quarter and six months ended June 30, 2018.
- GlobeNewswire•3 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within Community Health, Monotype Imaging, Cardlytics, Sanchez Energy, First Horizon National, and Aradigm — New Research Emphasizes Economic Growth
NEW YORK, July 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Community ...
- GlobeNewswire•3 months ago
New Research Coverage Highlights ProPetro Holding, Aradigm, Ocean Power Technologies, Icahn Enterprises, Granite Point Mortgage Trust, and PBF Logistics LP — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, July 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ProPetro ...
- Business Wire•4 months ago
Aradigm Announces the Appointment of Dr. Theresa Matkovits to the Board of Directors
Aradigm Corporation (ARDM) (the "Company") today announced the appointment of Dr. Theresa Matkovits to the Board, the Audit Committee of the Board and the Nominating and Corporate Governance Committee of the Board. Dr. Matkovits is Chief Operating Officer of ContraVir Pharmaceuticals (“ContraVir”). Dr. Matkovits has served as ContraVir’s Chief Operating Officer since December 2017, previous to which, she served as Executive Vice President, Head of Drug Development at ContraVir from May 2015 to November 2017.
- Associated Press•5 months ago
Aradigm: 1Q Earnings Snapshot
The Hayward, California-based company said it had a loss of 32 cents per share. The specialty pharmaceutical company posted revenue of $1.5 million in the period. The company's shares closed at $1.47. ...
- Business Wire•5 months ago
Aradigm Announces First Quarter 2018 Financial Results
Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2018.
- ACCESSWIRE•6 months ago
Wired News – EMA Completed Validation of MAA for Aradigm’s Linhaliq in Non-Cystic Fibrosis Bronchiectasis
Stock Monitor: Bio-Path Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Aradigm Corp. (NASDAQ: ARDM ). If you ...
- Business Wire•7 months ago
Aradigm Announces the EMA Has Completed Its Validation of the MAA Submission
Aradigm Corporation today announced the completed formal validation by the European Medicines Agency of the Marketing Authorisation Application for Linhaliq for the treatment of non-cystic fibrosis bronchiectasis patients with chronic lung infections with Pseudomonas aeruginosa (P.
- Associated Press•7 months ago
Aradigm reports 4Q loss
On a per-share basis, the Hayward, California-based company said it had a loss of 28 cents. The specialty pharmaceutical company posted revenue of $2.4 million in the period. For the year, the company ...
- Business Wire•7 months ago
Aradigm Announces Fourth Quarter 2017 and Full Year Financial Results
Aradigm Corporation today announced financial results for the fourth quarter and full year ended December 31, 2017.
- ACCESSWIRE•7 months ago
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation And Reminds Investors With Losses To Contact The Firm
LOS ANGELES, CA / ACCESSWIRE / March 12, 2018 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aradigm Corporation ("Aradigm" ...
- ACCESSWIRE•7 months ago
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aradigm Corporation (ARDM) & Lead Plaintiff Deadline: March 12, 2018
NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Aradigm Corporation (''Aradigm'' or the ''Company'') ...
- Zacks•7 months ago
Aradigm Files MAA for Bronchiectasis Candidate in the EU
Aradigm (ARDM) submits regulatory applications for its bronchiectasis candidate, Linhaliq, in the EU. A response from the EMA is awaited within 21 days to notify if the filing is complete.
- ACCESSWIRE•7 months ago
The Klein Law Firm Reminds Shareholders of Aradigm Corporation of a Class Action and a Lead Plaintiff Deadline of March 12, 2018 (ARDM)
NEW YORK, NY / ACCESSWIRE / March 12, 2018 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Aradigm Corporation (NASDAQ: ARDM) who purchased shares ...
- Business Wire•7 months ago
Glancy Prongay & Murray LLP Reminds Investors of the March 12, 2018 Deadline in the Class Action Lawsuit Against Aradigm Corporation
Glancy Prongay & Murray LLP reminds investors of the March 12, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Aradigm Corporation securities between July 27, 2017 and January 8, 2018, inclusive .
- ACCESSWIRE•7 months ago
MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation And Reminds Investors With Losses To Contact The Firm
LOS ANGELES, CA / ACCESSWIRE / March 10, 2018 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aradigm Corporation ("Aradigm" ...
- Business Wire•7 months ago
ARADIGM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Aradigm Corporation to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aradigm Corporation of the March 12, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- Business Wire•7 months ago
March 12th Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aradigm Corporation (ARDM)
Law Offices of Howard G. Smith reminds investors of the March 12, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Aradigm Corporation securities between July 27, 2017 and January 8, 2018, inclusive .
- ACCESSWIRE•7 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Aradigm Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 12, 2018 - ARDM
NEW YORK, NY / ACCESSWIRE / March 9, 2018 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Aradigm Corporation ...
- ACCESSWIRE•7 months ago
DEADLINE REMINDER NOTICE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation And Reminds Investors With Losses To Contact The Firm
LOS ANGELES, CA / ACCESSWIRE / March 9, 2018 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aradigm Corporation ("Aradigm" ...
- Business Wire•7 months ago
Aradigm Submits Marketing Authorisation Application (MAA) to EMA for EU Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
Aradigm Corporation today announced it has submitted its Marketing Authorisation Application to European Medicines Agency for Linhaliq™ for the treatment of non-cystic fibrosis bronchiectasis patients with chronic lung infection with Pseudomonas aeruginosa (P.
